APA (7th ed.) Citation

Motzer, R. J., McDermott, R., Park, S. H., Burotto, M., Iacovelli, R., Verzoni, E., . . . Westgeest, H. M. (2026). Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): An open-label, randomised, controlled, phase 3 trial. Lancet, 408(10557), 808. https://doi.org/10.1016/S0140-6736(26)01089-5

Chicago Style (17th ed.) Citation

Motzer, Robert J., et al. "Belzutifan Plus Lenvatinib Versus Cabozantinib in Patients with Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-011): An Open-label, Randomised, Controlled, Phase 3 Trial." Lancet 408, no. 10557 (2026): 808. https://doi.org/10.1016/S0140-6736(26)01089-5.

MLA (9th ed.) Citation

Motzer, Robert J., et al. "Belzutifan Plus Lenvatinib Versus Cabozantinib in Patients with Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-011): An Open-label, Randomised, Controlled, Phase 3 Trial." Lancet, vol. 408, no. 10557, 2026, p. 808, https://doi.org/10.1016/S0140-6736(26)01089-5.